(Q40494620)
Statements
Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease (English)
Martens LL
1 November 1994
1052-62; discussion 1036